p19 INK4D/CDKN2D Antibody (E-3): sc-271566

p19 INK4D Antibody (E-3) is a mouse monoclonal IgG2a antibody that detects p19 INK4D in mouse and rat samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p19 INK4D plays a crucial role in regulating the cell cycle by specifically inhibiting the kinase activities of cyclin-dependent kinases Cdk4 and Cdk6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. This inhibition helps prevent uncontrolled cell proliferation, a hallmark of cancer. p19 INK4D expression reaches maximum levels during the S phase, and p19 INK4D overexpression can lead to G1 arrest, thereby acting as a critical checkpoint in cellular growth and division. The gene encoding p19 INK4D is located on chromosome 9p21.3, a region frequently associated with chromosomal abnormalities in various human tumors, highlighting p19 INK4D significance in cancer research. Through interactions with key regulatory proteins in the cell cycle, p19 INK4D serves as an important target for studies aimed at understanding cell cycle dynamics and the mechanisms underlying tumorigenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p19 INK4D/CDKN2D Antibody (E-3) References:

1. Molecular cloning and characterization of the human p19(INK4d) gene promoter.  |  Matsuzaki, Y., et al. 2002. FEBS Lett. 517: 272-6. PMID: 12062451
2. Cranial neural crest-derived mesenchymal proliferation is regulated by Msx1-mediated p19(INK4d) expression during odontogenesis.  |  Han, J., et al. 2003. Dev Biol. 261: 183-96. PMID: 12941628
3. p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.  |  Felisiak-Golabek, A., et al. 2013. Cancer Biol Ther. 14: 973-81. PMID: 24022213
4. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.  |  Dreidax, D., et al. 2014. Hum Mol Genet. 23: 6826-37. PMID: 25104850
5. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma.  |  Zhou, H., et al. 2018. Cell Prolif. 51: e12447. PMID: 29484736
6. p19INK4d: More than Just a Cyclin-Dependent Kinase Inhibitor.  |  Han, X., et al. 2020. Curr Drug Targets. 21: 96-102. PMID: 31400265
7. p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia.  |  Kuang, Y., et al. 2020. Blood Cells Mol Dis. 85: 102477. PMID: 32711219
8. Profiling senescent cells in human brains reveals neurons with CDKN2D/p19 and tau neuropathology.  |  Dehkordi, SK., et al. 2021. Nat Aging. 1: 1107-1116. PMID: 35531351
9. Comparative detection and quantitation of human CDK inhibitor mRNA expression of p15INK4B, p16INK4A, p16beta, p18INK4C, p19INK4D, p21WAF1, p27KIP1 and p57KIP2 by RT-PCR using a polycompetitive internal standard.  |  Schwaller, J., et al. 1997. Br J Haematol. 99: 896-900. PMID: 9432039
10. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression.  |  Arora, T. and Jelinek, DF. 1998. J Biol Chem. 273: 11799-805. PMID: 9565604

The preferred p19 INK4D/CDKN2D antibody is p19 INK4D/CDKN2D Antibody (DCS-100): sc-56334.